Mark Hamann
Mark T. Hamann
(843) 876-2316
hamannm@musc.edu
280 Calhoun Street, Pharmacy Building Room QF 301
Faculty email addresses should not be used to seek medical advice or to make medical appointments. Please visit MyChart for medical appointments or to contact your provider.
Department
-
COP Drug Discovery and Biomedical Sciences
Academic Focus
-
The discovery, design, synthesis and development of new natural products with activity against cancer, infectious disease and neurological disorders. Exploration of remote regions of the ocean for new therapeutics. Culture and characterization of the human, plant and marine invertebrate microbiomes.
-
The development and application of state-of-the-art NMR and MS techniques that expedite the discovery, dereplication and structure assignment of new natural products. Targets of interest for bioaffinity screening for broad-spectrum controls of coronaviruses include proteases and methyl transferases
-
The synthesis, medicinal chemistry and optimization of natural products with unique mechanisms of action against cancer, infectious disease and neurological disorders. Development of synthetic methods to make complex natural products.
Faculty email addresses should not be used to seek medical advice or to make medical appointments. Please visit MyChart for medical appointments or to contact your provider.
Biography
Dr. Mark T. Hamann serves as the Charles and Carol Cooper/SmartState Endowed Chair of Drug Discovery and Biomedical Sciences at the MUSC College of Pharmacy. He also holds Adjunct appointments with The University of Maryland’s Institute of Marine and Environmental Technology and the Bigelow Marine Laboratory in Maine. Dr. Hamann began his career in GMP pharmaceutical manufacturing at Solvay Pharmaceuticals in Baudette, Minnesota and then completed a Ph.D. degree in Organic Chemistry at the University of Hawaii, under the guidance of the late Professor Paul J. Scheuer. During his graduate studies he discovered the lead anticancer agent, kahalalide F which entered clinical trials with the help of the biotech company PharmaMar. Dr. Hamann completed Postdoctoral Studies with Prof Bill Baker at McMurdo Station in Antarctica and then spent 20 years as a faculty member and natural products researcher at The University of Mississippi School of Pharmacy. During his research career, Dr. Hamann has published over 250 scientific papers, reviews, book chapters and guided over 100 graduate students/postdoctoral fellows and visiting scholars. Dr. Hamann currently serves as an Associate Editor for Biochimica et Biophysica Acta, General Subjects. His group is actively involved in the isolation, structure determination and optimization through synthesis of natural products and toxins with a focus on plant and invertebrate microbiomes. His group is currently working on the preclinical development of a small pipeline of natural products with activity against cancer, emerging infectious diseases and neuropsychiatric disorders.
|